HOME >> MEDICINE >> NEWS
AstraZeneca announces SYMBICORT is now available in the US

Wilmington, Del. June 25, 2007 -- AstraZeneca announced today that SYMBICORT (budesonide/formoterol fumarate dihydrate) pressurized metered dose inhaler (pMDI) is now available in the United States for the long-term maintenance treatment of asthma in patients 12 years of age and older.

Administered twice daily, SYMBICORT is a combination of two proven asthma medications budesonide, an inhaled corticosteroid (ICS), and formoterol, a rapid and long-acting beta2-agonist (LABA). For many patients, this combination treatment offers improved asthma control as early as day one that is sustained over 12 weeks. SYMBICORT also delivers improved lung function occurring within 15 minutes of beginning treatment. SYMBICORT does not replace fast-acting inhalers for sudden attacks.

SYMBICORT is available in two dose strengths, 80/4.5 and 160/4.5 mcg of budesonide and formoterol, respectively. SYMBICORT is approved for patients whose disease is not adequately controlled on another asthma-controller medication (e.g., low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies.

With the U.S. launch of SYMBICORT, millions of asthma sufferers will have a new choice of fixed combination therapy to help achieve control of their asthma, said Chris OBrien, MD, PhD, senior director, Medical Science, AstraZeneca.

Asthma is one of the most serious chronic diseases in the U.S. It is estimated that more than 20 million Americans suffer from the condition and, if not properly managed, asthma can be life-threatening.

The U.S. availability of SYMBICORT holds great promise for millions of Americans that suffer from asthma, said Tony Zook, president and chief executive officer, AstraZeneca U.S. The addition of SYMBICORT to our respiratory portfolio reinforces AstraZenecas commitment to developing new, effective treatments, and provides patients and physicians
'"/>

Contact: Tracy Knudsen
Tracy.Knudsen@astrazeneca.com
302-885-1933
AstraZeneca
25-Jun-2007


Page: 1 2

Related medicine news :

1. AstraZeneca, University of Miami, and Humana collaborate to improve consumer health
2. AstraZeneca and M. D. Anderson Cancer Center form umbrella scientific collaboration agreements
3. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
4. Weill Cornell Medical College announces gifts totaling $400M
5. GSK announces launch of largest ever Phase III trial in lung cancer treatment
6. Elsevier announces launch of Brain Stimulation
7. NSW Premier announces $15M for childrens cancer research
8. National Inventors Hall of Fame announces 2007 inductees
9. Emory University announces new Global Health Institute
10. BioMed Central announces Journal of Medical Case Reports
11. Tibotec Therapeutics announces start of largest US study on HIV treatment in women

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: AstraZeneca announces SYMBICORT now available the

(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... a top review from Clinicians Report of Provo, Utah. The Clinicians Report is ... a selected group of dentists located throughout the U.S. Whiter Image's In-Office whitening ...
(Date:9/3/2015)... ... 2015 , ... James Earl Jones will be hosting an upcoming VOICES IN ... Jones will introduce a segment that discusses why it is important for the workplace ... be fostered in any working environment. , Employers are out billions of dollars year ...
(Date:9/2/2015)... ... 03, 2015 , ... The Aspen Clinic (TAC), located in Basalt, ... kick-starting and inspiring wellness in the Roaring Fork Valley and beyond. , Amanda Wagner, ... mind-body approach to fitness - we are much more than a gym. Our ...
(Date:9/2/2015)... CA (PRWEB) , ... September 02, 2015 , ... The ... genome by using a complex of the Cas9 nuclease with either a chimeric single ... RNA (tracrRNA)). The ability of any given guide RNA (sgRNA or crRNA) to create ...
(Date:9/2/2015)... , ... September 02, 2015 , ... Based in Beverly ... fleet of truly superb luxury vehicles based on which of the latest and greatest ... the latest step forward in pursuit of this goal: a 2015 Rolls Royce ...
Breaking Medicine News(10 mins):Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... of the "Medical Device Studies: Clinical Evidence ... to their offering. This course ... involved in gathering clinical evidence required for medical ... required for all medical devices and the emphasis ...
(Date:9/2/2015)... Sept. 2, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... Chief Financial Officer of Neurocrine Biosciences, will be presenting ... New York City . The live ... ET (8:25am PT).  The presentation will be webcast and ... http://www.neurocrine.com .   Listeners are encouraged to ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/r6wspz/drug_delivery_in ) has ... "Drug Delivery in Central Nervous System Diseases ... offering. Advances in understanding of ... new avenues and possibilities for improved drug delivery ... enzymes, and receptors that control the penetration of ...
Breaking Medicine Technology:Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3
Cached News: